Memory CD8+ T cell response found as early as two weeks after the first administration of EO2401, expanding to up to 5% of circulating specific CD8+ T cells in some patients Immunological
PARIS, Sept. 16, 2022 /PRNewswire/ Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform
EO2401 is a first-in-class OncoMimics therapeutic cancer vaccine able to significantly expand existing effector memory CD8+ T cells directed at OncoMimics peptides corresponding to tumor-associated
Enterome is evaluating EO2401 in Phase 1/2 clinical trials in recurrent glioblastoma (ROSALIE) and adrenocortical malignancies (SPENCER)Proof-of-concept data in both trials of EO2401 have demonstrated
Data highlights strong immune responses and early signs of clinical benefit, establishing proof-of-concept OncoMimics immunotherapy pipeline generated using Enterome's unique microbiome